Erasca, Inc. (ERAS) stock analysis
In our weekly check, Erasca, Inc. is graded D (A to F). Of 18 checks on debt, profit, cash flow and trend: 7 pass, warnings: 1, red flags: 10.
About Erasca, Inc.
Erasca, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as ERAS.
What our checks show for ERAS
Red flags
- Weak EPS forecast
- Analysts expect the net margin to shrink by 10311 points from today's 0%.
- Earnings per share fell 20.8% a year over the last 3 years.
- The company has no revenue yet.
- Free cash flow is negative and the company has no revenue yet: it lives on its cash and new funding.
- The price swings a lot: 125% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 96% from a peak. Would you have held through that?
- The share count grew by 88.8% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- The stock is still below its previous peak.
Strengths
- Debt is low: 0.05x equity.
- Beta 0.65: the stock usually moves less than the market.
- Actively traded: about 4.8 million shares a day.
Similar companies
MANE · PTCT · SRRK · DNTH · COGT · EWTX
Questions
What grade does Erasca, Inc. (ERAS) have?
In our weekly check, Erasca, Inc. is graded D (A to F). Of 18 checks on debt, profit, cash flow and trend: 7 pass, warnings: 1, red flags: 10. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of ERAS stock?
This week's biggest flags for Erasca, Inc.: Weak EPS forecast, Margins expected to shrink, Weak EPS growth. In total 11 of 18 checks show a warning or a red flag.
What does Erasca, Inc. do?
Erasca, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as ERAS.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis